CSafe Global appoints Amy DuRoss as CGT President
DuRoss will oversee CSafe's CGT solutions portfolio in her new job, supporting intelligent transport of high-value tailored therapeutics and vaccines in order to satisfy the unprecedented global supply chain transport complexity of CGT goods.
Amy DuRoss has joined CSafe Global as President, Cell and Gene Therapies (CGT). CSafe Global is the innovation leader in temperature-controlled shipping solutions for the transport of life-enhancing pharmaceuticals.
DuRoss will oversee CSafe's CGT solutions portfolio in her new job, supporting intelligent transport of high-value tailored therapeutics and vaccines in order to satisfy the unprecedented global supply chain transport complexity of CGT goods.
DuRoss joins the company with over 25 years of expertise. She was the co-founder and CEO of Vineti, an enterprise software platform used to digitise chain of identification and chain of custody standards for CGT goods, before to joining CSafe. DuRoss formerly served as Chief Business Officer of Navigenics, Chief of Staff at the California Institute for Regenerative Medicine (CIRM), and Co-Founder, Co-Author, and Executive Director of California's $3 billion stem cell research ballot initiative.
"We are delighted to have Amy leading our CGT team. Her diverse experience in both corporate development, patient advocacy and entrepreneurship is exactly the right mix to drive innovation and superior solutions in this deeply complex supply chain," said CSafe CEO, Patrick Schafer. "We expect to see significant strides forward in this portfolio under Amy's strategic guidance."
"I'm honored to have the opportunity to collaborate with the world-class team at CSafe Global in bringing a new standard of high-quality, high-value supply chain transport to the most exciting innovation area in personalized medicine, cell and gene therapies," said DuRoss said, "CSafe Global's outstanding worldwide service network and proven expertise in robust and actionable analytics to drive supply chain efficiencies will hasten the industrialization of an emergent market that offers critical hope for an increasing number of patients in need."
DuRoss graduated from Stanford University with a bachelor's degree, two master's degrees, and an MBA. She serves on the boards of Biolife Solutions (BLFS), MJH, Americans for Cures, and the ARM Foundation, and is a member of the Aspen Institute Global Network.